SequelSEC

Propanc Biopharma, Inc. PPCB

Pharmaceutical Preparations · CIK 0001517681 · Fiscal year ends 0630

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2026-03-31
Operating income
-$6.40M
Fiscal year ended 2026-03-31
Free cash flow
-$1.14M
Fiscal year ended 2026-03-31

Propanc Biopharma, Inc. (PPCB) reported net income of -$6.36M for the fiscal year ended 2026-03-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from Propanc Biopharma, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Propanc Biopharma, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
RevenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating income-$6.40MUnavailableUnavailable-$3.65M-$53.13MUnavailableUnavailable-$259.90K-$420.87KUnavailable
Net income-$6.36MUnavailableUnavailable-$4.07M-$54.07MUnavailableUnavailable-$358.58K-$526.70KUnavailable
Research & development$169.66KUnavailableUnavailable$53.52K$54.10KUnavailableUnavailable$52.39K$65.45KUnavailable
Weighted-average diluted sharesshares 22.43MUnavailableUnavailableUnavailableshares 4.33MUnavailableUnavailableUnavailableUnavailableUnavailable
Pretax income-$6.36MUnavailableUnavailable-$4.07M-$54.07MUnavailableUnavailable-$358.82K-$526.98KUnavailable
Income tax expenseUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable-$237-$275Unavailable
Diluted EPS$-0.28UnavailableUnavailableUnavailable$-12.50UnavailableUnavailableUnavailable$-545.79Unavailable
Selling, general & administrativeUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
General & administrative$6.22MUnavailableUnavailable$3.59M$53.07MUnavailableUnavailable$192.94K$348.84KUnavailable
Selling & marketingUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Balance

Propanc Biopharma, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Cash & equivalentsUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Total assets$14.33MUnavailableUnavailable$19.63M$22.53MUnavailableUnavailable$72.36K$37.34KUnavailable
Current assets$8.22MUnavailableUnavailable$8.35M$9.74MUnavailableUnavailable$25.44K$12.86KUnavailable
Total liabilities$3.51MUnavailableUnavailable$5.73M$4.44MUnavailableUnavailable$3.85M$3.74MUnavailable
Current liabilities$3.48MUnavailableUnavailable$5.58M$4.34MUnavailableUnavailable$3.79M$3.69MUnavailable
Total equity incl. NCI$9.83MUnavailableUnavailable$13.91M$18.09MUnavailableUnavailable-$3.78M-$3.70MUnavailable
Temporary (mezzanine) equity$1.00MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
InventoryUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt$55.00KUnavailableUnavailable$537.92K$438.58KUnavailableUnavailable$399.32K$582.95KUnavailable
Accounts payable$973.69KUnavailableUnavailable$1.25M$1.12MUnavailableUnavailable$1.21M$1.19MUnavailable

Cash flow

Propanc Biopharma, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Operating cash flow-$1.14MUnavailableUnavailable-$92.19K-$96.20KUnavailableUnavailable-$259.97K-$102.81KUnavailable
Capital expenditures$154UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Investing cash flow-$154UnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Financing cash flow$981.61KUnavailableUnavailable$72.76K$147.48KUnavailableUnavailable$250.97K$66.64KUnavailable
Net change in cash-$117.54KUnavailableUnavailable-$38.67K$36.13KUnavailableUnavailable$14.86K-$65.43KUnavailable
Stock-based compensation$1.77MUnavailableUnavailable$3.12MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common dividends paidUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Derived

Propanc Biopharma, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-302024-06-302024-03-312023-12-31
Free cash flow-$1.14MUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Gross marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Current ratio2.37xUnavailableUnavailable1.50x2.24xUnavailableUnavailable0.01x0.00xUnavailable
Revenue YoY growthUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Long-term debt / equity0.01xUnavailableUnavailable0.04xUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open PPCB in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-05-14View SEC filing
10-Q · Filed 2026-02-17View SEC filing
10-Q · Filed 2025-11-14View SEC filing
10-K · Filed 2025-09-29View SEC filing
10-Q · Filed 2025-05-15View SEC filing
10-Q · Filed 2025-02-14View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Reconciliation checks needing review

16 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.

balance equationinconsistent2025-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2025-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2025-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2024-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2024-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-12-31

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-12-31

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.

balance equationinconsistent2023-09-30

Withheld: assets, equity, liabilities could not be reconciled with the rest of this filer’s statement.

gross profit bridgeinconsistent2023-09-30

Withheld: cost revenue, revenue could not be reconciled with the rest of this filer’s statement.